Johnson & Johnson $JNJ Shares Sold by Diversified Trust Co

Diversified Trust Co cut its stake in shares of Johnson & Johnson (NYSE:JNJ) by 20.6% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 89,296 shares of the company’s stock after selling 23,233 shares during the period. Johnson & Johnson comprises about 0.5% of Diversified Trust Co’s holdings, making the stock its 28th biggest holding. Diversified Trust Co’s holdings in Johnson & Johnson were worth $23,640,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in JNJ. Vista Capital Partners Inc. acquired a new stake in Johnson & Johnson in the 3rd quarter worth about $1,609,000. Astra Wealth Partners LLC raised its holdings in shares of Johnson & Johnson by 4.5% during the third quarter. Astra Wealth Partners LLC now owns 1,385 shares of the company’s stock valued at $367,000 after acquiring an additional 60 shares during the last quarter. McElhenny Sheffield Capital Management LLC lifted its position in shares of Johnson & Johnson by 19.4% in the third quarter. McElhenny Sheffield Capital Management LLC now owns 1,677 shares of the company’s stock valued at $444,000 after acquiring an additional 273 shares in the last quarter. 10Elms LLP lifted its position in shares of Johnson & Johnson by 6.8% in the third quarter. 10Elms LLP now owns 1,263 shares of the company’s stock valued at $334,000 after acquiring an additional 80 shares in the last quarter. Finally, Aberdeen Group plc boosted its stake in shares of Johnson & Johnson by 8.5% in the third quarter. Aberdeen Group plc now owns 2,654,448 shares of the company’s stock worth $702,739,000 after acquiring an additional 207,390 shares during the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Trading Up 0.8%

Shares of Johnson & Johnson stock opened at $285.78 on Friday. The stock has a market cap of $687.95 billion, a P/E ratio of 43.30, a P/E/G ratio of 2.80 and a beta of 0.22. The stock’s 50 day simple moving average is $266.97 and its 200-day simple moving average is $249.85. Johnson & Johnson has a 1-year low of $193.55 and a 1-year high of $288.11. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.02 and a quick ratio of 0.74.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, beating the consensus estimate of $2.53 by $0.06. Johnson & Johnson had a return on equity of 31.64% and a net margin of 16.20%. The firm had revenue of $25.40 billion during the quarter, compared to analysts’ expectations of $25.38 billion. During the same quarter last year, the firm earned $2.80 earnings per share. The business’s revenue for the quarter was up 5.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Analysts predict that Johnson & Johnson will post 11.12 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be issued a $1.34 dividend. This represents a $5.36 annualized dividend and a yield of 1.9%. The ex-dividend date is Tuesday, November 24th. Johnson & Johnson’s dividend payout ratio is presently 81.21%.

Wall Street Analyst Weigh In

Several brokerages recently commented on JNJ. Johnson Rice cut Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Wednesday, October 21st. Wall Street Zen lowered Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Saturday, August 1st. Weiss Ratings cut shares of Johnson & Johnson from a “buy (b+)” rating to a “buy (b-)” rating in a research note on Friday, October 23rd. Guggenheim reaffirmed a “buy” rating and set a $287.00 target price on shares of Johnson & Johnson in a report on Wednesday, October 7th. Finally, Erste Group Bank cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Wednesday, October 21st. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $275.92.

Recent Johnson & Johnson Headlines

Here are a few of the latest headlines about JNJ:

• Positive Sentiment: J&J is backing Francis Medical as it advances a water-vapor prostate-cancer treatment device toward FDA premarket approval. The investment expands its reach in minimally invasive oncology treatment. J&J leads Francis Medical investment to fund prostate cancer device
• Neutral Sentiment: J&J also led a $100 million funding round for Delix Therapeutics’ depression-drug development. This broadens its exposure to emerging psychiatric treatments, but clinical-stage programs carry substantial execution risk. Johnson & Johnson Backs New Cancer Device And Leads $100 Million Depression Bet
• Negative Sentiment: Pomerantz LLP said it is investigating claims on behalf of J&J investors. The notice provides no specific findings, but litigation-related uncertainty may weigh on sentiment. Pomerantz Law Firm Investigates Claims on Behalf of Johnson & Johnson Investors

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Elizabeth Forminard sold 13,072 shares of the firm’s stock in a transaction on Thursday, November 12th. The stock was sold at an average price of $284.39, for a total value of $3,717,546.08. Following the completion of the sale, the executive vice president directly owned 16,994 shares of the company’s stock, valued at $4,832,923.66. This trade represents a 43.48% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Jennifer Taubert sold 15,000 shares of Johnson & Johnson stock in a transaction on Monday, August 17th. The stock was sold at an average price of $263.36, for a total value of $3,950,400.00. Following the transaction, the executive vice president owned 194,451 shares in the company, valued at approximately $51,210,615.36. This represents a 7.16% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 61,669 shares of company stock valued at $16,898,386 in the last three months. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Profile

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.